Long Shortz with Racura Oncology: Understanding the mechanism of action that could transform cancer therapy

Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully to discuss the groundbreaking discovery of the primary mechanism of action of their lead drug.

Dr Tillett explains how understanding the drug’s mechanism increases the probability of clinical success, allowing Racura to identify the cancer types most likely to respond, develop predictive biomarkers, and design more effective combination therapies.

Watch the full video here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@racuraoncology.com T: +61 2 8051 3043
© 2026 Racura Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Racura Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.